ClariTrial | Search Clinical Trials

Explore/cardiovascular heart disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

588 results for “cardiovascular heart disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 40

Recruiting

The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

Phase 3Zhejiang University

Fexofenadine 60 Mg Oral TabletPlacebo

Second Affiliated Hospital, Zhejiang University, School of Medicine2,804 participants1 site · ChinaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

Phase 3Cardiogenic Shock

Empagliflozin 10 MG

Central Hospital, Nancy, France164 participants8 sites · FranceCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

Phase 3Type 2 DiabetesCardiovascular Risk

ZenagamtideInsulin glargine U-100

Novo Nordisk A/S1,778 participants330 sites · United States, Argentina, BrazilCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Phase 2Heart Failure

CDR132LPlacebo

Novo Nordisk A/S200 participants118 sites · United States, Canada, GermanyCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

Phase 2THCCannabisCannabis Use

CannabisNicotinePax Loose Leaf Vaporizer+1 more

University of California, San Francisco48 participants1 site · United StatesCompletes Feb 2028

Compare CT.gov Full analysis →

Recruiting

Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery

Phase 3Cardiovascular DiseasesCardiovascular ComplicationPerioperative Complication

ColchicinePlacebo

Cantonal Hospital of St. Gallen880 participants1 site · SwitzerlandCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)

Phase 2Congenital Diaphragmatic HerniaPulmonary Hypertension

Sildenafil Oral SuspensionPlacebo

University of Utah40 participants1 site · United StatesCompletes Mar 2026

Compare CT.gov Full analysis →

Recruiting

Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

Phase 2Coronary Artery Disease

Mepolizumab low dose groupMepolizumab middle dose groupMepolizumab high dose group+1 more

Xijing Hospital18 participants1 site · ChinaCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia

Phase 2Hypertension

Eplerenone 100 mg dailyChlorthalidone 25 mg dailyPotassium Placebo+1 more

Massachusetts General Hospital90 participants2 sites · United StatesCompletes Mar 2029

Compare CT.gov Full analysis →

Recruiting

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Phase 3Atrial FibrillationStrokeBleeding

Antiplatelet-only strategyOral Anticoagulant plus background antiplatelet therapy

Icahn School of Medicine at Mount Sinai3,200 participants106 sites · United States, Brazil, CanadaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Intranasal Dexmedetomidine on Blood Pressure in Elderly Hypertensive Patients Undergoing Cataract Surgery

Phase 3CataractHypertension

Intranasal dexmedetomidineIntranasal normal saline

Suez Canal University126 participants1 site · EgyptCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage

Phase 2Cerebral Amyloid AngiopathyIntracerebral Hemorrhage Lobar

Colchicine 0.5mgMatching placebo

Huashan Hospital80 participants3 sites · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Phase 2Chronic CholecystitisBiliary Dyskinesia

4-MUSTPlacebo

Valenta Pharm JSC300 participants17 sites · RussiaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2Endocrine TumorsNon-Small Cell Lung CancerOvarian Cancer

CyclophosphamideFludarabineAldesleukin+2 more

National Cancer Institute (NCI)285 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

Phase 2DyslipidemiasCardiovascular DiseasesHIV Infections

Bempedoic acidPlacebo

Priscilla Hsue, MD121 participants3 sites · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

1–15 of 588

Explore/cardiovascular heart disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

588 results for “cardiovascular heart disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 40

Recruiting

The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

Phase 3Zhejiang University

Fexofenadine 60 Mg Oral TabletPlacebo

Second Affiliated Hospital, Zhejiang University, School of Medicine2,804 participants1 site · ChinaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

Phase 3Cardiogenic Shock

Empagliflozin 10 MG

Central Hospital, Nancy, France164 participants8 sites · FranceCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Phase 3Type 2 DiabetesCardiovascular Risk

ZenagamtideInsulin glargine U-100

Novo Nordisk A/S1,778 participants330 sites · United States, Argentina, BrazilCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

Phase 2Heart Failure

CDR132LPlacebo

Novo Nordisk A/S200 participants118 sites · United States, Canada, GermanyCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

Phase 2THCCannabisCannabis Use

CannabisNicotinePax Loose Leaf Vaporizer+1 more

University of California, San Francisco48 participants1 site · United StatesCompletes Feb 2028

Compare CT.gov Full analysis →

Recruiting

Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery

Phase 3Cardiovascular DiseasesCardiovascular ComplicationPerioperative Complication

ColchicinePlacebo

Cantonal Hospital of St. Gallen880 participants1 site · SwitzerlandCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)

Phase 2Congenital Diaphragmatic HerniaPulmonary Hypertension

Sildenafil Oral SuspensionPlacebo

University of Utah40 participants1 site · United StatesCompletes Mar 2026

Compare CT.gov Full analysis →

Recruiting

Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

Phase 2Coronary Artery Disease

Mepolizumab low dose groupMepolizumab middle dose groupMepolizumab high dose group+1 more

Xijing Hospital18 participants1 site · ChinaCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia

Phase 2Hypertension

Eplerenone 100 mg dailyChlorthalidone 25 mg dailyPotassium Placebo+1 more

Massachusetts General Hospital90 participants2 sites · United StatesCompletes Mar 2029

Compare CT.gov Full analysis →

Recruiting

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Phase 3Atrial FibrillationStrokeBleeding

Antiplatelet-only strategyOral Anticoagulant plus background antiplatelet therapy

Icahn School of Medicine at Mount Sinai3,200 participants106 sites · United States, Brazil, CanadaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Intranasal Dexmedetomidine on Blood Pressure in Elderly Hypertensive Patients Undergoing Cataract Surgery

Phase 3CataractHypertension

Intranasal dexmedetomidineIntranasal normal saline

Suez Canal University126 participants1 site · EgyptCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage

Phase 2Cerebral Amyloid AngiopathyIntracerebral Hemorrhage Lobar

Colchicine 0.5mgMatching placebo

Huashan Hospital80 participants3 sites · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Phase 2Chronic CholecystitisBiliary Dyskinesia

4-MUSTPlacebo

Valenta Pharm JSC300 participants17 sites · RussiaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2Endocrine TumorsNon-Small Cell Lung CancerOvarian Cancer

CyclophosphamideFludarabineAldesleukin+2 more

National Cancer Institute (NCI)285 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

Phase 2DyslipidemiasCardiovascular DiseasesHIV Infections

Bempedoic acidPlacebo

Priscilla Hsue, MD121 participants3 sites · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

1–15 of 588